What Studies are Enrolling Right Now?

This phase II trial is studying how well acolbifene works in preventing cancer in premenopausal women at high risk of breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of acolbifene may stop cancer from growing or coming back. The principal investigator for the trial is Carol Fabian, MD, at University of Kansas Medical Center. 

See more details about the trial at Study Details | NCT00853996 | Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer | ClinicalTrials.gov 

Study sites that are open (or opening soon) and contacts at each site are as follows:

• University of Kansas, Kansas City, KS: Amy Kreutzjans akreutzjans@kumc.edu

• Northwestern University, Chicago IL: Sarah DeHorn sarah.dehorn@northwestern.edu

• Ohio State University, Columbus OH: Cevasco, Karly karly.cevasco@osumc.edu

• City of Hope, Duarte CA: Cynthia Basulto cbasulto@coh.org

This phase II trial evaluates low dose tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Low dose tamoxifen with or without omega-3 fatty acids may be effective at reducing risk of breast cancer among women who are postmenopausal, overweight or obese, and at increased risk.  The principal investigator for the trial is Lauren Nye, MD, at University of Kansas Medical Center. 

See more details about the trial at Study Details | NCT06195306 | Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | ClinicalTrials.gov 

Study sites that are open (or opening soon) and contacts at each site are as follows:

• University of Kansas, Kansas City, KS: Amy Kreutzjans akreutzjans@kumc.edu

• Ohio State University, Columbus OH: Cevasco, Karly karly.cevasco@osumc.edu